Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 825-833

  Nikitina, Ekaterina ^a   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

radiation; Apoptosis; Dendritic cells; Tumor immunology

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GAMMA IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SPLEEN CELL;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; GAMMA RAYS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL;

EID: 0035892360     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5     Document Type: Article

References (42)

1. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: The role of apoptosis
2. Enhancement of radiosensitizing effect of the nitroimidazole derivative RK28 on the proliferation of MethA tumor cells in combined use with diethyldithiocarbamate
3. Dendritic cells and the control of immunity
4. Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells
5. Therapy of murine tumors with p53 wildtype and mutant sequence peptide-based vaccines
6. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation and T hepler cell 1-associated cytokines
8. Dendritic cells pulsed with RNA and potent antigen-presenting cells in vitro and in vivo
9. 5 and CD36 and cross-present antigens to cytotoxic T lymphocytes
10. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
11. Dead or alive: Immunogenicity of human melanoma cells when pesented by dendritic cells
12. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
13. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
14. Local administration of dendritic cells inhibits established breast tumor growth: Implication for apoptosis-inducing agents
15. Serial in vivo observations of cerebral vasculature after treatment with a large single fraction of radiation
16. 8+ T cells
17. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
18. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
19. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
20. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
21. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells
22. Dose-response effects of radiation on the permeability of endothelial cells in culture
23. The effects of ionizing radiation on the pulmonary vasculature of intact rats and isolated pulmonary endothelium
24. + T cells
25. H2-M mutant mice are defective in the peptide loading of class II molecules antigen presentation and T cell repertoire selection
26. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
27. Decreased antigen presentation by dendritic cells in patients with breast cancer
28. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
29. Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells
30. Clinical significance of defective dendritic cell differentiation in cancer
31. Dendritic Cells transduced with full-length wildtype p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients
32. Radiation induced endothelial retraction in vitro: Correlation with acute pulmonary edema
33. Regulation of dendritic cell trafficking: A process that involves the participation of selective chemokines
34. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection
35. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes
36. Natural adjuvants: Endogenous activators of dendritic cells
37. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes
38. The induction of tolerance by dendritic cells that have captured apoptotic cells
39. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
40. Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity
41. Necrotic, but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
42. Regulation of endothelial cell function by pro- and anti-inflammatory cytokines